NASDAQ:ARRY - Array Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.99 +0.99 (+5.21 %)
(As of 06/21/2018 02:11 AM ET)
Previous Close$19.00
Today's Range$18.85 - $20.18
52-Week Range$7.15 - $20.18
Volume5.47 million shs
Average Volume3.26 million shs
Market Capitalization$3.69 billion
P/E Ratio-27.76
Dividend YieldN/A
Beta1.79
Array Biopharma logoArray BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Debt-to-Equity Ratio0.36
Current Ratio5.73
Quick Ratio5.73

Price-To-Earnings

Trailing P/E Ratio-27.76
Forward P/E Ratio-27.01
P/E GrowthN/A

Sales & Book Value

Annual Sales$150.85 million
Price / Sales27.91
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book285.57

Profitability

EPS (Most Recent Fiscal Year)($0.72)
Net Income$-116,810,000.00
Net Margins-72.33%
Return on Equity-96.65%
Return on Assets-31.97%

Miscellaneous

Employees209
Outstanding Shares210,640,000

Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) posted its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.11. The biopharmaceutical company earned $66.37 million during the quarter, compared to analysts' expectations of $28.81 million. Array Biopharma had a negative return on equity of 96.65% and a negative net margin of 72.33%. Array Biopharma's revenue for the quarter was up 99.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.21) earnings per share. View Array Biopharma's Earnings History.

When is Array Biopharma's next earnings date?

Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Array Biopharma.

What price target have analysts set for ARRY?

8 equities research analysts have issued twelve-month price objectives for Array Biopharma's shares. Their predictions range from $13.00 to $24.00. On average, they expect Array Biopharma's stock price to reach $18.3750 in the next year. View Analyst Ratings for Array Biopharma.

What are Wall Street analysts saying about Array Biopharma stock?

Here are some recent quotes from research analysts about Array Biopharma stock:
  • 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (5/14/2018)
  • 2. Cantor Fitzgerald analysts commented, "ARRY and ASLAN (NC) have updated a 2011 agreement for varlitinib, a pan-HER2 inhibitor, providing nearer term cash to ARRY in exchange for commercialization rights (the prior agreement covered development)." (1/3/2018)

Are investors shorting Array Biopharma?

Array Biopharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 15,870,987 shares, an increase of 21.4% from the April 30th total of 13,075,730 shares. Based on an average trading volume of 2,971,569 shares, the short-interest ratio is currently 5.3 days. Currently, 7.7% of the company's shares are short sold. View Array Biopharma's Current Options Chain.

Who are some of Array Biopharma's key competitors?

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:
  • Mr. Ron Squarer, Chief Exec. Officer and Director (Age 51)
  • Mr. Jason Haddock, Chief Financial Officer (Age 48)
  • Mr. Andrew R. Robbins, Chief Operating Officer (Age 42)
  • Dr. Victor Sandor M.D., C.M, Chief Medical Officer (Age 52)
  • Dr. Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 59)

Has Array Biopharma been receiving favorable news coverage?

News stories about ARRY stock have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Array Biopharma earned a coverage optimism score of 0.14 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.91 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Array Biopharma's major shareholders?

Array Biopharma's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.68%), Franklin Resources Inc. (3.96%), BVF Inc. IL (2.44%), Farallon Capital Management LLC (1.47%), Pinnacle Associates Ltd. (1.25%) and Northern Trust Corp (1.17%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.

Which institutional investors are selling Array Biopharma stock?

ARRY stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BVF Inc. IL, venBio Select Advisor LLC, Franklin Resources Inc., Eversept Partners LLC, Pinnacle Associates Ltd., Trexquant Investment LP and Russell Investments Group Ltd.. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma.

Which institutional investors are buying Array Biopharma stock?

ARRY stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, American Century Companies Inc., Columbus Circle Investors, Neuberger Berman Group LLC, BlackRock Inc., PointState Capital LP, A.R.T. Advisors LLC and UBS Group AG. View Insider Buying and Selling for Array Biopharma.

How do I buy shares of Array Biopharma?

Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $19.99.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $3.69 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Array Biopharma employs 209 workers across the globe.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (ARRY)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  541
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.